Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BRKR stock price vs NTRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTRA's multiple
Needs NTRA P/S.
Implied fair value · at BRKR's multiple
Needs BRKR P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRUKER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NATERA, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
BRKR vs TMO
DANAHER CORP /DE/
BRKR vs DHR
AGILENT TECHNOLOGIES, INC.
BRKR vs A
WATERS CORP /DE/
BRKR vs WAT
BIO-RAD LABORATORIES, INC.
BRKR vs BIO
BIO-TECHNE Corp
BRKR vs TECH
ILLUMINA, INC.
BRKR vs ILMN
EXACT SCIENCES CORP
BRKR vs EXAS
AMGEN INC
BRKR vs AMGN
VERTEX PHARMACEUTICALS INC / MA
BRKR vs VRTX
REGENERON PHARMACEUTICALS, INC.
BRKR vs REGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BRKR can sustain its positive margins and modest growth without pressure from its 5.0x net debt/EBITDA, then BRKR is more attractive operationally than NTRA; however, the current price already sits near BRKR’s historical upper band, so upside looks limited unless you also believe NTRA-implied valuation framework is the right anchor.
The valuation gap is extreme on the provided P/S basis: BRKR trades at 2.4x sales versus NTRA at 20.1x, yet the supplied implied price for BRKR is $455.78, far above its current $53.41. That disconnect suggests the valuation output may be mechanically driven by NTRA multiple assumptions rather than BRKR’s own fundamentals or trading history.
Supporting Metrics
